Ars Pharmaceuticals, Inc.
A maker of neffy, the first FDA-approved needle-free nasal spray for emergency treatment of severe allergic reactions (anaphylaxis), replacing the familiar auto-injector shot. Founded in 2015 by Richard Lowenthal, Dr. Sarina Tanimoto, and Dr. Robert Bell, the company's name is understood to reflect its focus on the allergic reaction system. neffy marked the first significant innovation in epinephrine delivery in over 35 years, offering a needle-free option for people who fear or avoid injectors.
Granted 3.01M · Bought 7.85M
Granted 12.56M · Sold 2.05M
Granted 13.41M · Sold 2.05M
Bought 500.0K · Sold 952.4K
Bought 500.0K · Sold 952.4K
Sold 1.30M
Granted 10.16M
Granted 3.01M
Bought 2.0K
Granted 1.07M · Sold 943.9K
Granted 695.6K · Sold 695.6K
Granted 100.0K · Bought 86.3K · Sold 106.3K
Granted 83.2K
Granted 54.9K
Granted 61.6K
Granted 54.4K
Granted 35.8K
Granted 87.5K · Bought 8.3K · Sold 87.5K
Granted 95.0K · Sold 95.0K
Granted 141.8K · Sold 141.8K
Granted 120.0K · Sold 120.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kolchinsky Peter +4 co-filersDirector, 10% owner, Director · 8 transactions | — | 21.03Mas of Mar 2024 | 3.01M | 7.85M | — |
| Tanimoto SarinaCHIEF MEDICAL OFFICER, 10% owner · 89 transactions | — | 20.36Mas of Aug 2025 | 12.56M | — | 2.05M |
| Lowenthal Richard EPRESIDENT AND CEO, Director, 10% owner · 88 transactions | — | 20.31Mas of Aug 2025 | 13.41M | — | 2.05M |
| Thompson Peter A.Director · 6 transactions | — | 17.61Mas of Aug 2024 | — | 500.0K | 952.4K |
| Orbimed Advisors LLC +2 co-filersDirector · 6 transactions | — | 17.53Mas of Aug 2024 | — | 500.0K | 952.4K |
| Deerfield Management Company, L.P. (Series C) +5 co-filers10% owner · 10 transactions | — | 9.77Mas of Jun 2025 | — | — | 1.30M |
| Pratik Shah Living Trust dated June 15, 2011 +1 co-filer10% owner, Director, 10% owner · 2 transactions | — | 7.49Mas of Jun 2024 | 10.16M | — | — |
| Shah PratikDirector · 5 transactions | — | 4.57M | — | — | — |
| Dadoo RajeevDirector · 1 transaction | — | 3.01Mas of Nov 2022 | 3.01M | — | — |
| Root Jonathan DDirector · 3 transactions | — | 2.27Mas of Mar 2022 | — | 2.0K | — |
| Shawver LauraDirector · 52 transactions | +165.5% | 210.3Kas of Apr 2025 | 1.07M | — | 943.9K |
| Chakma JustinChief Business Officer · 24 transactions | — | 166.4K | 695.6K | — | 695.6K |
| Fitzpatrick Alexander AChief Legal Officer · 5 transactions | — | 90.9K | 100.0K | 86.3K | 106.3K |
| Kelly MichaelDirector · 1 transaction | — | 83.2Kas of Nov 2022 | 83.2K | — | — |
| Piazza JonathanChief Financial Officer · 2 transactions | +481.5% | 69.2Kas of May 2022 | 54.9K | — | — |
| Odegard ValeriePresident and CSO · 2 transactions | — | 61.6Kas of May 2022 | 61.6K | — | — |
| Hunder NaomiChief Medical Officer · 2 transactions | — | 54.4Kas of May 2022 | 54.4K | — | — |
| Hawkinson RussSr. Vice President of Finance · 2 transactions | +18525.5% | 37.3Kas of May 2022 | 35.8K | — | — |
| Scott Kathleen D.Chief Financial Officer · 9 transactions | — | 26.5Kas of Aug 2025 | 87.5K | 8.3K | 87.5K |
| Karas EricChief Commercial Officer · 16 transactions | — | 12.2K | 95.0K | — | 95.0K |
| Dorsey BrianChief Operating Officer · 10 transactions | — | 10.8K | 141.8K | — | 141.8K |
| Saunders Brent LDirector · 2 transactions | — | 0as of May 2025 | 120.0K | — | 120.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -557.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.